NIKKEI 225
37,891.61 -568.47 (-1.48%) HANG SENG
17,144.12 -57.15 (-0.33%) CRUDE OIL
82.76 -0.05 (-0.06%) GOLD FUTURES
2,330.80 -7.60 (-0.33%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,789.44 -1,751.42 (-3.27%)
Atea Pharmaceuticals, Inc. (AVIR)
After hours:
| Previous close | 3.7300 |
| Open | 3.7100 |
| Bid | 3.6900 x 200 |
| Ask | 3.7400 x 100 |
| Day's range | 3.6800 - 3.7350 |
| 52-week range | 2.7650 - 5.1900 |
| Volume | |
| Avg. volume | 401,187 |
| Market cap | 313.934M |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.6300 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
GlobeNewswireAtea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H’24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleoti
Insider MonkeyAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript February 28, 2024 Atea Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update […]
- GuruFocus.com
Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results
Highlights Clinical Progress and Financial Position
